Simplex Trading’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-1,026
Closed -$9K – 8845
2020
Q1
$9K Buy
+1,026
New +$10.1K ﹤0.01% 6577
2018
Q3
– Sell
-358
Closed -$6K – 8447
2018
Q2
$6K Sell
358
-811
-69% -$16.3K ﹤0.01% 6663
2018
Q1
$24K Buy
+1,169
New +$22.9K ﹤0.01% 3198
2017
Q4
– Sell
-31
Closed – – 7070
2017
Q3
$0 Sell
31
-274
-90% -$6.57K ﹤0.01% 7027
2017
Q2
$8K Buy
+305
New +$9.9K ﹤0.01% 4231
2016
Q3
– Sell
-2,720
Closed -$175K – 6798
2016
Q2
$175K Sell
2,720
-2,811
-51% -$173K 0.01% 1082
2016
Q1
$400K Buy
+5,531
New +$410K 0.03% 537

Simplex Trading's ZBIO Position: Q2 2020 in Review

Simplex Trading sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q2 2020, closing a stake of 1,026 shares — an estimated $9K sold.

Simplex Trading first reported a position in ZBIO in Q1 2016 and held it in 7 quarters. The position peaked at $400K in Q1 2016. 0 funds tracked by Wall St. Rank hold ZBIO as of Q2 2020.

  • Simplex Trading reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q2 2020 after selling out during the quarter.
  • Simplex Trading sold 1,026 ProShares UltraPro Short NASDAQ Biotechnology shares in Q2 2020, an estimated $9K.
  • Simplex Trading first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q1 2016 and held it in 7 quarters.
  • Simplex Trading's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $400K in Q1 2016.
  • 0 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q2 2020.

Based on Simplex Trading's 13F filing for Q2 2020, filed 13 Jul 2020.